FLAV-27 Reverses Memory Decline in Alzheimer’s Mice by Blocking G9a
Updated
Updated · ZME Science · May 14
FLAV-27 Reverses Memory Decline in Alzheimer’s Mice by Blocking G9a
3 articles · Updated · ZME Science · May 14
University of Barcelona researchers reported that FLAV-27 restored short-term, long-term and spatial memory in Alzheimer’s-like mice, including animals treated after symptoms had already appeared.
By blocking the G9a enzyme, FLAV-27 targets the epigenome rather than just amyloid plaques, aiming to reactivate genes neurons need for memory, communication and repair.
Lab and animal tests also showed lower amyloid beta, tau and phosphorylated tau, reduced inflammation and cellular stress, and stronger synapse-related structures such as neurites, spines and branching.
Two blood markers—H3K9me2 and SMOC1—shifted with treatment in animals and were elevated in human Alzheimer’s samples, suggesting a possible way to select patients and track drug activity.
FLAV-27 remains preclinical: it has not been tested in people, and Flavii Therapeutics, a 2025 University of Barcelona spin-off, must complete safety and regulatory work before human trials.
Can a new drug truly reverse brain damage by resetting its genetic control system?
Is this compound the first step towards an era of epigenetic medicine for brain diseases?
FLAV-27’s Breakthrough: Reversing Memory Loss in Alzheimer’s Disease via Epigenetic Reprogramming
Overview
FLAV-27 is a groundbreaking experimental compound that has shown the ability to reverse memory decline in preclinical mouse models of Alzheimer’s disease, offering new hope for patients. Unlike current approved treatments such as lecanemab and donanemab, which are monoclonal antibodies that remove beta-amyloid plaques and only slow cognitive decline by about 27% to 35%, FLAV-27 works through a novel mechanism. It targets the enzyme G9a to reprogram the neuronal epigenome, aiming to correct gene expression changes linked to Alzheimer’s. This innovative approach could represent a major shift in how the disease is treated.